Sortaggable VSG Vesicles for Targeted Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy delivery systems face challenges such as inefficient loading, limited targeting capabilities, and scalability issues, particularly with adenoviruses and lipid nanoparticles, necessitating a more effective and targeted delivery method.
Innovation Solution
The development of vesicles derived from recombinant Trypanosoma brucei cells expressing sortaggable VSG, which are prepared through a method involving hypotonic lysis, sonication, and purification steps to create nanoVAST vesicles with a homogeneous surface structure, enabling efficient loading and targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If adenoviruses or AAV are used for gene delivery, then targeting capability is improved, but loading efficiency deteriorates and immunogenicity issues arise
Solution Approach 1:
The patent extracts the cell membrane component from trypanosomatid parasites to create vesicles that inherit the natural targeting capability of the parasite membranes while removing the problematic viral genome packaging step. This extraction allows the membrane vesicles to be loaded with therapeutic nucleic acids through electroporation without the immunogenicity and scalability issues of viral systems.
Solution Approach 2:
The patent uses an intermediary approach by employing trypanosomatid membrane vesicles as a carrier system between the therapeutic cargo and target cells. These vesicles serve as a natural intermediary that provides both protection for the cargo and targeting capability, eliminating the need for direct viral infection mechanisms.
2Ease of operation
If viral vectors are used for gene therapy, then targeting specificity is improved, but scalability and production cost deteriorate
Solution Approach 1:
The patent employs a disposable, non-replicating vesicle system that can be produced in large quantities through simple cell lysis and purification steps. Unlike viral vectors that require complex cell culture and purification processes, these membrane vesicles can be scaled up using standard parasitology protocols, significantly reducing production costs and improving scalability.
3Ease of manufacture
If conventional drug delivery systems are used, then ease of manufacture is improved, but targeting capability and delivery efficiency deteriorate
Solution Approach 1:
The patent changes the fundamental parameters of the delivery system by using membrane vesicles with natural surface proteins that recognize target cell receptors. This transforms conventional non-specific delivery into targeted delivery while maintaining ease of manufacture through simple vesicle preparation protocols that do not require complex conjugation chemistry.
4Productivity
If lipid nanoparticles are used for delivery, then loading efficiency is improved, but targeting capability deteriorates
Solution Approach 1:
The patent creates a composite delivery system where the vesicle membrane contains both the targeting components (natural surface proteins) and the cargo loading capability. The vesicle structure itself serves as the composite material that combines protection, targeting, and cargo delivery functions in a single system, eliminating the need for separate targeting molecules conjugated to lipid nanoparticles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoVAST vesicles provide efficient cargo delivery with cell-type specificity, overcoming limitations of existing systems by ensuring stable, targeted delivery of therapeutic agents like nucleic acids and proteins, while being scalable and cost-effective.
Implementation Method 1
treating said cells in hypotonic solution in the presence of at least one protease inhibitor until the cells are lysed
Implementation Method 2
treating the suspended cellular membranes obtained in the previous step with sonication in order to obtain a vesicle suspension
Data Source
AI summary
The present invention concerns the development of vesicles that could be used for generation of vaccines or as compound delivery vehicles. More specifically, the invention relates to a method for preparing a vesicle comprising the steps of: providing recombinant Trypanosoma brucei cells expressing sortaggable VSG, treating said cells in hypotonic solution in the presence of at least one protease inhibitor until the cells are lysed, isolating the cellular membranes from the solution, suspending the isolated membranes previously obtained in a isotonic solution, treating the suspended cellular membranes obtained in the previous step with sonication in order to obtain a vesicle suspension, removing aggregated membranous debris from the vesicle suspension previously obtained, separating the vesicle suspension into populations of vesicles, and providing vesicles from a population of vesicles which is characterized by the following parameters: (i) having a single predominant protein revealed after Coomassie staining an SDS PAGE that has an apparent molecular weight of 55 to 60 kDa, (ii) having a spherical appearance in electron micrographs and (iii) exhibiting a homogenous surface structure in electron micrographs. Moreover, the present invention also relates to a vesicle comprising sortaggable VSG characterized by the aforementioned parameters as well as such a vesicle for use in treating and/or preventing a disease or medical condition or as a compound delivery vesicle, preferably, drug delivery vehicle, more preferably, nucleic acid delivery vesicle. Finally, the invention contemplates a kit for carrying out the method of the present invention comprising recombinant Trypanosoma brucei cells expressing sortaggable VSG and at least one agent for carrying out the method of the present invention or a kit comprising the vesicle of the present invention.